TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Controlled Trial in Rural Burkina Faso to Determine the Optimal Amount of Zinc to Include in a Lipid-based Nutrient Supplement (LNS). Part of the iLiNS Study
Brief Summary: To assess zinc-related biochemical and functional responses among young Burkinabe children with a presumed high risk of zinc deficiency who receive micronutrient products containing different amounts of zinc, provided with or between meals.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Child's health and nutrition topics | Arm Label: PROMIS intervention; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Small-Quantity Lipid-based nutrient supplement, Behavioral: Child's health and nutrition topics | Intervention Type: DIETARY_SUPPLEMENT; Name: Small-Quantity Lipid-based nutrient supplement; Assigned to Arm(s): PROMIS intervention | Intervention Type: BEHAVIORAL; Name: Child's health and nutrition topics; Assigned to Arm(s): Control, PROMIS intervention
B: Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyNut; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: PlumpyDoz; Assigned to Arm(s): N/A
C: Arm Label: LNS-Zn5; Type: EXPERIMENTAL; Interventions: Dietary Supplement: LNS-Zn5 | Arm Label: LNS-Zn10; Type: EXPERIMENTAL; Interventions: Dietary Supplement: LNS-Zn10 | Arm Label: LNS-Zn0; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: LNS-Zn0 | Arm Label: Suppl-Zn5; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Suppl-Zn5 | Arm Label: Delayed intervention group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Zn5; Assigned to Arm(s): LNS-Zn5 | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Zn10; Assigned to Arm(s): LNS-Zn10 | Intervention Type: DIETARY_SUPPLEMENT; Name: LNS-Zn0; Assigned to Arm(s): LNS-Zn0 | Intervention Type: DIETARY_SUPPLEMENT; Name: Suppl-Zn5; Assigned to Arm(s): Suppl-Zn5
D: Arm Label: ST-DI; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: FSm; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Milk-containing fortified spread | Arm Label: FSs; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Soy-containing fortified spread | Arm Label: LP; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Maize-soy flour | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk-containing fortified spread; Assigned to Arm(s): FSm | Intervention Type: DIETARY_SUPPLEMENT; Name: Soy-containing fortified spread; Assigned to Arm(s): FSs | Intervention Type: DIETARY_SUPPLEMENT; Name: Maize-soy flour; Assigned to Arm(s): LP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Community-based Intervention Trial to Compare the Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children in Burkina Faso
Brief Summary: Zinc supplementation can either be provided in a lower daily dose to prevent zinc deficiency or in a higher dose for 10-14 days as part of the treatment of diarrhea. It is important to determine how best to integrate programs designed either to prevent zinc deficiency or to treat diarrhea.

The overall objective of this project is to determine the most effective approach to prevent zinc deficiency and treat diarrhea, such that a single approach could provide the maximal beneficial impact on the health and nutritional status of young children and greatest simplicity of implementation.


Options:
A: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A
B: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 10 mg zinc oxide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 10 mg zinc oxide; Assigned to Arm(s): Active | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Daily preventive Zn; placebo treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Daily preventive Zn; placebo treatment | Arm Label: Therapeutic Zn; daily placebo; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Therapeutic Zn; daily placebo | Arm Label: Intermittent Zn; placebo treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Intermittent Zn; placebo treatment | Arm Label: Surveillance control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Surveillance control group | Arm Label: Non-intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Daily preventive Zn; placebo treatment; Assigned to Arm(s): Daily preventive Zn; placebo treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Therapeutic Zn; daily placebo; Assigned to Arm(s): Therapeutic Zn; daily placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Intermittent Zn; placebo treatment; Assigned to Arm(s): Intermittent Zn; placebo treatment | Intervention Type: OTHER; Name: Surveillance control group; Assigned to Arm(s): Surveillance control group
D: Arm Label: Multivitamins; Type: EXPERIMENTAL; Interventions: Drug: Multivitamins - vitamins B complex, C and E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Multivitamins - vitamins B complex, C and E; Assigned to Arm(s): Multivitamins | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Use of Plasma Zinc Concentration for Assessing the Impact of Targeted and Mass Zinc Fortification Programs
Brief Summary: The purpose of the study is to evaluate the use of plasma zinc concentration for assessing the impact of targeted zinc fortification programs.


Options:
A: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Folic Acid | Arm Label: C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin B12 | Arm Label: D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Folic acid and vitamin B12 | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic Acid; Assigned to Arm(s): B | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin B12; Assigned to Arm(s): C | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: Folic acid and vitamin B12; Assigned to Arm(s): D
B: Arm Label: Zinc fortified group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Zinc fortified food, Other: Placebo supplement | Arm Label: Non-fortified group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo supplement, Dietary Supplement: Non-fortified food | Arm Label: Zinc supplement group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Zinc supplement, Dietary Supplement: Non-fortified food | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc fortified food; Assigned to Arm(s): Zinc fortified group | Intervention Type: DIETARY_SUPPLEMENT; Name: Zinc supplement; Assigned to Arm(s): Zinc supplement group | Intervention Type: OTHER; Name: Placebo supplement; Assigned to Arm(s): Non-fortified group, Zinc fortified group | Intervention Type: DIETARY_SUPPLEMENT; Name: Non-fortified food; Assigned to Arm(s): Non-fortified group, Zinc supplement group
C: Arm Label: Active; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 10 mg zinc oxide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 10 mg zinc oxide; Assigned to Arm(s): Active | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: zinc | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: iron + copper | Intervention Type: DIETARY_SUPPLEMENT; Name: zinc; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: iron + copper; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Relapse Prevention With Varenicline
Brief Summary: This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline(Chantix) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline(Chantix); Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Arm Label: No Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Intervention Type: BEHAVIORAL; Name: NH Medicaid Incentives Program; Assigned to Arm(s): Incentives, No Incentives

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Relapse Prevention With Varenicline
Brief Summary: This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.


Options:
A: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Varenicline + Active Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Varenicline | Arm Label: Varenicline + Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Varenicline + Active Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Patch, Varenicline + Placebo Patch
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Relapse Prevention With Varenicline
Brief Summary: This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: bupropion SR, Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Arm Label: II; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Group Therapy, Drug: nicotine replacement therapy | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): I | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Group Therapy; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: nicotine replacement therapy; Assigned to Arm(s): I, II
C: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
D: Intervention Type: DRUG; Name: SSR591813L (dianicline); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Relapse Prevention With Varenicline
Brief Summary: This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Relapse Prevention With Varenicline
Brief Summary: This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Arm A (bupropion hydrochloride); Type: EXPERIMENTAL; Interventions: Drug: Bupropion Hydrochloride, Other: Laboratory Biomarker Analysis, Other: Quality-of-Life Assessment, Other: Questionnaire Administration | Arm Label: Arm B (varenicline, NRT); Type: ACTIVE_COMPARATOR; Interventions: Other: Laboratory Biomarker Analysis, Drug: Nicotine Replacement, Other: Questionnaire Administration, Drug: Varenicline | Intervention Type: DRUG; Name: Bupropion Hydrochloride; Assigned to Arm(s): Arm A (bupropion hydrochloride) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (bupropion hydrochloride), Arm B (varenicline, NRT) | Intervention Type: DRUG; Name: Nicotine Replacement; Assigned to Arm(s): Arm B (varenicline, NRT) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm A (bupropion hydrochloride) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm A (bupropion hydrochloride), Arm B (varenicline, NRT) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Arm B (varenicline, NRT)
C: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
D: Arm Label: Varenicline & nicotine patches; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patches | Arm Label: Varenicline & placebo patches; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo (nicotine patches) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline & nicotine patches, Varenicline & placebo patches | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Varenicline & nicotine patches | Intervention Type: DRUG; Name: Placebo (nicotine patches); Assigned to Arm(s): Varenicline & placebo patches

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Relapse Prevention With Varenicline
Brief Summary: This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.


Options:
A: Arm Label: Varenicline Tartrate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline Tartrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline Tartrate; Assigned to Arm(s): Varenicline Tartrate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Varenicline | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Sugar pill

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Exercise Training on Non-invasive Cardiac Measures in Patients Undergoing Long-term Hemodialysis: A Randomized Controlled Trial
Brief Summary: Background: The impact of the known non-invasive cardiac indices for identification of hemodialysis (HD) patients at high-risk for sudden cardiac death (SCD) has not been evaluated.

Patients: Fifty-nine HD patients were randomized into 2 groups. Thirty of them (group A-aged 54.6±8.9 years) participated in a supervised training program with stationary bicycles during their HD sessions (3/weekly) for 10 months, while the rest (group B-aged 53.2±6.1 years) remained untrained and were used as controls.

Study hypothesis: Exercise training will affect most of the non-invasive cardiac markers of SCD and the total score positively.

Method: At entry, as well as at the end of the study all subjects underwent a cardiopulmonary exercise testing (estimation of aerobic capacity-VO2peak), an echocardiographic study (LV ejection fraction -LVEF evaluation), an ambulatory 24-hour Holter monitoring for cardiac autonomic nervous system activity evaluation by time- and frequency- domain heart rate variability (HRV) calculation (measurement of SDNN, mean RR and low to high frequency ratio-LF/HF), a signal-averaged ECG (late potentials-LP documentation) and a submaximal exercise test for microvolt-T-wave alternans (TWA) detection.


Options:
A: Arm Label: HD-Exercise-HDF; Type: EXPERIMENTAL; Interventions: Procedure: Intra-dialytic exercise | Intervention Type: PROCEDURE; Name: Intra-dialytic exercise; Assigned to Arm(s): HD-Exercise-HDF
B: Arm Label: Dopamine Agonist Group; Type: EXPERIMENTAL; Interventions: Other: Dopamine Agonist and Exercise | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Dopamine Agonist and Exercise | Intervention Type: OTHER; Name: Dopamine Agonist and Exercise; Assigned to Arm(s): Dopamine Agonist Group, Placebo Group
C: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: activity group; Type: EXPERIMENTAL; Interventions: Device: Exercise training in addition to nutritional support | Intervention Type: DEVICE; Name: Exercise training in addition to nutritional support; Assigned to Arm(s): activity group
D: Arm Label: exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training | Arm Label: controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training; Assigned to Arm(s): exercise training

Answer: D